

Exhibit A:



- 4. (Amended) The method of claim [1, 2 or] 3, wherein the subject is [a non-human animal, a transgenic non-human animal or] a human.--
- 5. (Amended) The method of claim [1, 2 or] 3, wherein the subject has undergone an angioplasty procedure or has undergone surgery to implant a stent in a blood vessel.--
- 9. (Amended) The method of claim [1, 2 or] 3, wherein the inhibitor is the V-domain of soluble receptor for advanced glycation endproduct (sRAGE).--
- 11. (Amended) The method of claim [1, 2 or] 3, wherein the inhibitor is administered to the subject by bolus injection, intraperitoneal injection, i.v., oral administration, topical application to the blood vessel, coating of a device to be placed within the subject, coating of an instrument used during a procedure upon the subject which results in blood vessel injury, or contacting blood of the subject during extracorporeal circulation.--
- 13. (Amended) The method of claim [1, 2 or] 3, wherein the inhibitor is administered to the subject at a rate from about 2  $\mu\text{g/kg/hr}$  to about 100  $\mu\text{g/kg/hr}$ .--

--14.(Amended) The method of claim [1, 2 or] 3, wherein the inhibitor is coated onto a stent used during an angioplasty of the subject.--